Skip to main content

Advertisement

SpringerLink
Log in

Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Objective

To determine the incidence of serous tubal intraepithelial carcinoma (STIC) after risk reduction salpingo-oophorectomy(RRSO), and to describe oncological outcomes after RRSO.

Materials and methods

BRCA pathogenic mutation carriers who had undergone an RRSO were evaluated in this retrospective multicenter observational study. Patients were only included when fallopian tubes were analyzed following the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM). Surgeries were performed between June 2010 and April 2017 at eight Spanish hospitals.

Results

A total of 359 patients met the inclusion criteria. STIC was diagnosed in 3 (0.8%) patients; one of them underwent surgical staging due to positive peritoneal washing, with absence of disease at the final pathology report. None of the three patients received adjuvant chemotherapy and were free of disease at last follow-up. Fallopian tube and ovarian carcinoma were diagnosed in 5 (1.4%) and 1 (0.3%), respectively. At a median (range) follow-up time of 29 (3–92) months, five patients had a newly diagnosed breast cancer. Other types of cancer, which were diagnosed during the follow-up time, included: serous primary peritoneal carcinoma (n = 1), serous endometrial carcinoma (n = 1), colon (n = 1), pancreas (n = 1), jaw (n = 1), and lymphoma (n = 1). Seven patients died due to different types of cancer: breast (n = 4), pancreas (n = 1), jaw (n = 1), and colon (n = 1).

Conclusion

The incidence of STIC after RRSO in BRCA mutation carriers is low (0.8%) and it presents an excellent oncological outcome. Patients after RRSO, however, run the risk to develop other types of cancer during follow-up and should be properly advised before the prophylactic surgery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24(Suppl 10):x16–21.

    Article  Google Scholar 

  2. Morrison JC, Blanco LZ Jr, Vang R, Ronnett BM. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series. Am J Surg Pathol. 2015;39(4):442–53.

    Article  Google Scholar 

  3. Li HX, Lu ZH, Shen K, Cheng WJ, Malpica A, Zhang J, et al. Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis. Int J Clin Exp Pathol. 2014;7(3):848–57.

    PubMed  PubMed Central  Google Scholar 

  4. Patrono MG, Corzo C, Iniesta M, Ramirez PT. Management of preinvasive lesions. Clin Obstet Gynecol. 2017;60(4):771–9.

    Article  Google Scholar 

  5. Patrono MG, Iniesta MD, Malpica A, Lu KH, Fernandez RO, Salvo G, et al. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): a comprehensive review. Gynecol Oncol. 2015;139(3):568–72.

    Article  Google Scholar 

  6. Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, et al. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol Oncol. 2016;143(2):231–5.

    Article  Google Scholar 

  7. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30(2):230–6.

    Article  Google Scholar 

  8. National Comprehensive Cancer Network (NCCN). Genetic/familial high-risk assessment: breast and ovarian. https://www.nccn.org/store/login/login.aspx?. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf. Accessed Jan 2018.

  9. Mehrad M, Ning G, Chen EY, Mehra KK, Crum CP. A pathologist’s road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010;17(5):293–302.

    Article  CAS  Google Scholar 

  10. College of American Pathologists. Protocol for the examination of specimens from patients with carcinoma of the fallopian tube. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/fallopiantube-15protocol-3102.pdf. Accessed 10 March 2018.

  11. Prat J. FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124(1):1–5.

    Article  Google Scholar 

  12. Powell CB, Swisher EM, Cass I, McLennan J, Norquist B, Garcia RL, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129(2):364–71.

    Article  CAS  Google Scholar 

  13. King J, Wynne CH, Assersohn L, Jones A. Hormone replacement therapy and women with premature menopause—a cancer survivorship issue. Eur J Cancer. 2011;47(11):1623–32.

    Article  CAS  Google Scholar 

  14. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.

    Article  CAS  Google Scholar 

  15. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hereditary breast cancer clinical study group. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst. 2008;100(19):1361–7.

    Article  CAS  Google Scholar 

  16. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2005;23(31):7804–10.

    Article  CAS  Google Scholar 

  17. Chlebowski RT, Prentice RL. Menopausal hormone therapy in BRCA1 mutation carriers: uncertainty and caution. J Natl Cancer Inst. 2008;100(19):1341–3.

    Article  CAS  Google Scholar 

  18. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358–65.

    Article  CAS  Google Scholar 

  19. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94(18):1365–72.

    Article  CAS  Google Scholar 

  20. Blok F, Roes EM, van Leenders GJ, van Beekhuizen HJ. The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review. BMC Cancer. 2016;14(16):18.

    Article  Google Scholar 

  21. Reitsma W, de Bock GH, Oosterwijk JC, Bart J, Hollema H, Mourits MJ. Support of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer. 2013;49(1):132–41.

    Article  Google Scholar 

  22. Jazaeri AA, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, et al. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia. 2011;13(10):899–911.

    Article  CAS  Google Scholar 

  23. Powell CB, Chen LM, McLennan J, Crawford B, Zaloudek C, Rabban JT, et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011;21(5):846–51.

    Article  Google Scholar 

  24. The Pelvic-Ovarian Cancer Interception (POINT) Project. http://www.bwhpathology.org/POINT/point_purpose.aspx. Accessed Jan 2018.

Download references

Acknowledgements

The authors want to thank Lara Vargas, MD (Gynecology Department, Sanatorio Allende, Córdoba, Argentina) for her contribution in the manuscript.

Author information

Authors and Affiliations

  1. Gynecology Department, Instituto Valenciano de Oncología (IVO), C/del Profesor Beltrán Baguena 8, 46009, Valencia, Spain

    L. Minig & A. García-Garcia

  2. Gynecology Department, Hospital Universitario Vall d`Hebron, Barcelona, Spain

    S. Cabrera & B. Gil-Ibáñez

  3. Gynecology Department, Hospital Universitario, 12 de Octubre, Madrid, Spain

    R. Oliver

  4. Gynecology Department, Hospital Universitario Príncipe de Asturias de Alcalá de Henares, Madrid, Spain

    A. Couso

  5. Medical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain

    M. J. Rubio

  6. Gynecology Department, Hospital Universitario Quirón, Madrid, Spain

    S. Iacoponi

  7. Gynecology Department, Hospital Universitario de Getafe, Madrid, Spain

    M. B. Martin-Salamanca

  8. Gynecology Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Canarias (CHUIMI), Gran Canaria, Islas Canarias, Spain

    S. Carballo-Rastrilla

  9. Department of Applied Mathematics and Statistics, CEU San Pablo University, Madrid, Spain

    J. M. Cádenas-Rebollo

  10. Medical Oncology Department, Instituto Valenciano de Oncología (IVO), Valencia, Spain

    M. J. Juan-Fita

  11. Gynecology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

    M. G. Patrono

Authors
  1. L. Minig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Cabrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Oliver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Couso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. J. Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Iacoponi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. B. Martin-Salamanca
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Carballo-Rastrilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. M. Cádenas-Rebollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. García-Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Gil-Ibáñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M. J. Juan-Fita
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. M. G. Patrono
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Minig.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest.

Ethical approval

The study was previously approved by the Internal Review Board in accordance with the ethical standards of the Helsinki Declaration of 1975, revised in 1983.

Informed consent

For this type of study formal consent was not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minig, L., Cabrera, S., Oliver, R. et al. Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study. Clin Transl Oncol 20, 1337–1344 (2018). https://doi.org/10.1007/s12094-018-1865-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-018-1865-9

Keywords

Search

Navigation